WHAT IS IT?
Epigenetics refers to heritable changes in gene expression independent from DNA sequence.
The configuration of chromatin and its relationship with other proteins influences gene expression. Chromatin structure is modified through epigenetic regulators that affect DNA methylation, histone modifications, and noncoding RNA segments. Each class of epigenetic regulators alters chromatin configuration and affects the expression of genes in different ways. Therefore, studies of epigenetic modulations are critical for our understanding of regulatory gene mechanisms at the molecular, cellular, and organ levels. Or, in a broader sense, the coordinated actions of epigenetic regulators determine cell cycle regulation, cell death, and outcomes in health and disease
OUR PATENTS
Epigen has Successfully Filed 2 Patents
Details coming soon
our publications
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia…
W Chung, AD Kelly, P Kropf, H Fung, J Jelinek, XY Su, GJ Roboz, …Clinical epigenetics 11 (1), 106
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML …
GJ Roboz, H Döhner, M Gobbi, PL Kropf, J Mayer, J Krauter, T Robak, …Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …
Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice…
JP Issa, M Gobbi, PL Kropf, P Fenaux, GJ Roboz, J Mayer, J Krauter, …Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …
RESULTS OF ASTRAL-1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE…
P Fenaux, M Gobbi, PL Kropf, J Mayer, GJ Roboz, H Döhner, J Krauter, …HemaSphere 3, 394-395
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre…
G Garcia-Manero, G Roboz, K Walsh, H Kantarjian, E Ritchie, P Kropf, …The Lancet Haematology 6 (6), e317-e327
Phase I results of a multicenter clinical trial combining guadecitabine, a DNA methyltransferase inhibitor, with atezolizumab, an immune…
CL O’Connell, PL Kropf, N Punwani, D Rogers, R Sposto, K Grønbæk Blood 132 (Supplement 1), 1811-1811
Long term results of a randomized phase 2 dose-response study of guadecitabine, a novel subcutaneous (SC) hypomethylating agent …
G Garcia-Manero, EK Ritchie, KJ Walsh, MR Savona, HM Kantarjian, …Blood 132 (Supplement 1), 231-231
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia
RL Redner, JH Beumer, P Kropf, M Agha, M Boyiadzis, K Dorritie, R Farah, …
Phase 2 study of guadecitabine (SGI-110), a novel hypomethylating agent, in treatment-naïve patients with acute myeloid leukaemia who…
Prof. Hagop M Kantarjian, Prof. Gail J Roboz, Patricia L Kropf, Karen WL Yee, Casey L O’Connell, Raoul Tibes, Katherine J Walsh, Nikolai A Podoltsev, Elizabeth A Griffiths, Elias Jabbour, Prof…